Related Experiment Video
Updated: Feb 24, 2026
Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Caffeine use in the neonatal intensive care unit
Jalal M Abu-Shaweesh1, Richard J Martin2
1The Cleveland Clinic Foundation, Cleveland, OH, USA.
Insights
Caffeine use in neonatal intensive care units aids breathing and may reduce lung issues like bronchopulmonary dysplasia. While initial neurodevelopmental benefits fade, it shows lasting improvements in motor skills and coordination.
Area of Science:
- Neonatal Medicine
- Pharmacology
- Developmental Pediatrics
Background:
- Caffeine is a common medication in neonatal intensive care units (NICUs).
- It is primarily used for apnea of prematurity, with potential benefits for bronchopulmonary dysplasia (BPD) and patent ductus arteriosus (PDA).
- Long-term outcomes, including neurodevelopmental effects, require further investigation.
Purpose of the Study:
- To evaluate the efficacy and safety of caffeine in neonatal care.
- To assess the impact of caffeine on respiratory outcomes, survival, and neurodevelopmental trajectories.
- To explore the potential mechanisms of action for caffeine's observed effects.
Main Methods:
- Review of long-term studies on caffeine use in neonates.
- Analysis of data on incidence of BPD, PDA, and survival rates.
- Assessment of neurodevelopmental outcomes at various follow-up points (18-21 months and 5 years).
Main Results:
- Caffeine use is associated with reduced incidence of BPD and PDA, and improved survival.
- Sustained improvements in coordination and reduced gross motor impairment were observed at age 5.
- Neurodevelopmental advantages were not statistically significant at 5 years, but motor improvements persisted.
Conclusions:
- Caffeine is a safe and effective medication for neonatal apnea with potential benefits for BPD and neurodevelopment.
- Mechanisms may involve adenosine receptor inhibition, anti-inflammatory effects, white matter protection, and surfactant induction.
- Further research is needed to optimize caffeine dosing and treatment duration.
Abstract:
Caffeine is the most frequently used medication in the neonatal intensive care unit. It is used for the prevention and treatment of apnea, although this has been associated with lower incidence of bronchopulmonary dysplasia (BPD) and patent ductus arteriosus as well as intact survival at 18-21 months of life. Although neurodevelopmental advantage was no longer statistically significant at age 5 years, caffeine was associated with sustained improvement in co-ordination and less gross motor impairment than placebo. The mechanism of action of caffeine on prevention of apnea and activation of breathing seems to be through central inhibition of adenosine receptors. However, its impact on BPD and neurodevelopmental outcomes might be induced through its effects as anti-inflammatory mediator, protection of white matter, and induction of surfactant protein B. Whereas long-term studies have documented the safety of caffeine as used in current practice, further studies are clearly needed to identify optimum dosing, and time of starting and discontinuing caffeine.
More Related Videos
Related Concept Videos
01:29Drug Dosing: Infants and Children
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:24Parenteral Anesthetics: Overview